FDA Finds Long-Term Treatment with Clopidogrel Does Not Affect Risk of Death

November 13, 2015 | Strategic Insights for Ambulatory Care


​A recent U.S. Food and Drug Administration (FDA) evaluation of Plavix (clopidogrel) concluded that long-term use of the drug does not increase or decrease the overall risk of death in patients with, or at risk of, heart disease. According to a November 6, 2015, FDA drug safety communication, FDA's evaluation also found no evidence suggesting that the drug increases the risk of cancer or mortality related to cancer.

Access Full Content

Contact us today at 610.825.6000.